16 May 2025 - The outcome statement from the April 2025 DUSC meeting is now available.

The DUSC reviewed the following technologies:

• Single inhaler triple therapies for severe asthma
• Medicines for gastro-intestinal stromal tumour
• Zanubrutinib for Waldenström macroglobulinaemia

Read PBS News